Coeptis Therapeutics, Inc. (COEP)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Coeptis Therapeutics, Inc. (COEP) trades at $10.99 with AI Score 31/100 (Grade D). Coeptis Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing pharmaceutical products and cell therapy platforms for cancer patients. Market cap: $38.62M, Sector: Healthcare.
Price live · AI analysis from May 9, 2026Analyst Coverage for COEP: COEP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates COEP against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
COEP: 4/7 perspectives are bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Coeptis Therapeutics, Inc. (COEP) Healthcare & Pipeline Overview
Coeptis Therapeutics, Inc. is a biopharmaceutical company specializing in the development of cell therapy platforms and pharmaceutical products for cancer treatment. Their focus on CD38-related cancers, including multiple myeloma, positions them within the competitive biotechnology sector, leveraging collaborations for expanded therapeutic applications.
What Is the Investment Thesis for COEP?
Coeptis Therapeutics presents a high-risk, high-reward investment profile typical of early-stage biopharmaceutical companies. The company's focus on innovative cell therapy platforms, particularly CD38-GEAR-NK, offers potential for significant returns if clinical trials are successful. However, the company's negative profit margin of -611.1% and gross margin of -207.8% highlight the financial challenges inherent in drug development. Key value drivers include the successful advancement of CD38-GEAR-NK through clinical trials and the potential commercialization of CD38-Diagnostic. Collaborations with Statera BioPharma and Vici Health Sciences could also unlock additional value. Investors should closely monitor clinical trial results, regulatory milestones, and the company's ability to secure funding to sustain operations. The negative beta of -0.43 suggests a potential hedge during market downturns, but this should be weighed against the company's inherent volatility.
Based on FMP financials and quantitative analysis
COEP Key Highlights
- Market Cap of $38.62M reflects Coeptis Therapeutics' small size and early stage of development within the biotechnology sector.
- Profit Margin of -611.1% indicates significant losses, common for biopharmaceutical companies investing heavily in research and development.
- Gross Margin of -207.8% suggests that the cost of goods or services exceeds revenue, highlighting the need for successful product commercialization.
- Beta of -0.43 indicates that the stock price is negatively correlated with the market, potentially offering some downside protection during market declines.
- No Dividend Yield reflects the company's focus on reinvesting earnings into research and development rather than returning capital to shareholders.
Who Are COEP's Competitors?
COEP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| JNJ Johnson & Johnson | $258.13 | -1.87% | $621.38B | 90 |
| BMY Bristol-Myers Squibb Company | $56.73 | -2.40% | $115.86B | 88 |
| AMGN Amgen Inc. | $365.01 | -2.44% | $197.00B | 83 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are COEP's Key Strengths?
- Innovative cell therapy platforms.
- Focus on CD38-related cancers.
- Strategic collaborations with other companies.
- Development of companion diagnostics for personalized medicine.
What Are COEP's Weaknesses?
- Limited financial resources.
- Early stage of development with no approved products.
- High dependence on clinical trial success.
- Small number of employees.
What Could Drive COEP Stock Higher?
- Clinical trial results for CD38-GEAR-NK in multiple myeloma (expected Q4 2026).
- Regulatory submission for CD38-Diagnostic (expected Q2 2027).
- Progress in the development of STAT-201 for Crohn's disease in collaboration with Statera BioPharma.
- Advancement of CPT60621 for Parkinson's Disease in partnership with Vici Health Sciences, LLC.
What Are the Key Risks for COEP?
- Financial-distress signal — its Altman Z-Score of 0.75 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-89.6%) — the business is not currently generating profit on shareholder capital.
- Clinical trial failures for CD38-GEAR-NK or other pipeline candidates.
- Regulatory delays or rejection of marketing applications.
- Competition from established pharmaceutical companies with greater resources.
- Dependence on securing additional funding to sustain operations.
- Patent infringement or challenges to intellectual property rights.
What Are the Growth Opportunities for COEP?
- CD38-GEAR-NK Development: The primary growth opportunity lies in the successful development and commercialization of CD38-GEAR-NK for CD38-related cancers. The market for multiple myeloma treatment alone is projected to reach billions of dollars by 2030. Positive clinical trial results and regulatory approval could drive significant revenue growth for Coeptis. The timeline for this opportunity depends on the speed and success of clinical trials, with potential for initial market entry within the next 3-5 years.
- CD38-Diagnostic Commercialization: The commercialization of CD38-Diagnostic as an in vitro screening tool represents another key growth opportunity. By identifying patients most likely to benefit from anti-CD38 therapies, this diagnostic tool could improve treatment outcomes and reduce healthcare costs. The market for companion diagnostics is expanding rapidly, driven by the trend towards personalized medicine. Coeptis could potentially launch CD38-Diagnostic within the next 2-3 years, pending regulatory approval and commercial partnerships.
- STAT-201 for Crohn's Disease: The collaboration with Statera BioPharma to develop STAT-201 for Crohn's disease offers diversification and growth potential beyond oncology. The market for Crohn's disease therapies is substantial, with a growing demand for novel treatments. Successful clinical development and commercialization of STAT-201 could provide Coeptis with a new revenue stream and expand its therapeutic focus. Clinical trials are ongoing, with potential for market entry within the next 4-6 years.
- CPT60621 for Parkinson's Disease: The co-development of CPT60621 with Vici Health Sciences for Parkinson's Disease provides another avenue for growth. The market for Parkinson's disease treatments is expanding due to the aging population. If CPT60621 proves effective in clinical trials, it could generate significant revenue for Coeptis. The timeline for this opportunity is dependent on clinical trial progress, with potential for market entry in 5-7 years.
- Strategic Partnerships and Acquisitions: Coeptis can pursue strategic partnerships and acquisitions to expand its product pipeline and market reach. Collaborating with other biotechnology companies or acquiring promising drug candidates could accelerate growth and diversify risk. This strategy could involve licensing agreements, joint ventures, or outright acquisitions, depending on the specific opportunities that arise. The timeline for this growth opportunity is variable, depending on the availability of suitable targets.
What Opportunities Does COEP Have?
- Expanding market for cancer therapies.
- Growing demand for personalized medicine.
- Potential for strategic partnerships and acquisitions.
- Advancements in cell therapy technology.
What Threats Does COEP Face?
- Competition from established pharmaceutical companies.
- Regulatory hurdles and clinical trial failures.
- Patent expiration and generic competition.
- Economic downturn affecting healthcare spending.
What Are COEP's Competitive Advantages?
- Proprietary cell therapy platforms offer a technological advantage.
- Patent protection on key drug candidates and diagnostic tools.
- Strategic collaborations with established pharmaceutical companies.
- Focus on personalized medicine through diagnostic screening.
What Does COEP Do?
Founded in 2017 and headquartered in Wexford, Pennsylvania, Coeptis Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for cancer patients. The company's core focus lies in cell therapy platforms and pharmaceutical products designed to address unmet needs in oncology. Coeptis's lead product candidate is CD38-GEAR-NK, a Vy-Gen drug product targeting CD38-related cancers such as multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia. This therapy aims to leverage the body's immune system to fight cancer cells. In addition to CD38-GEAR-NK, Coeptis is developing CD38-Diagnostic, an in vitro screening tool designed to predict which cancer patients are most likely to benefit from anti-CD38 monoclonal antibody therapies. This diagnostic tool has the potential to personalize cancer treatment by identifying patients who will respond favorably to specific therapies. Coeptis also engages in strategic collaborations to expand its therapeutic pipeline. The company is collaborating with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease, diversifying its focus beyond oncology. Furthermore, Coeptis has partnered with Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease, indicating an interest in addressing neurological disorders as well. These collaborations are crucial for Coeptis, allowing them to leverage external expertise and resources to advance their product development efforts.
What Products and Services Does COEP Offer?
- Develops cell therapy platforms for cancer treatment.
- Commercializes generic and branded pharmaceutical products.
- Focuses on therapies for CD38-related cancers, including multiple myeloma.
- Develops in vitro screening tools to predict patient response to therapies.
- Collaborates with other companies to expand its therapeutic pipeline.
- Targets unmet needs in oncology and neurological disorders.
How Does COEP Make Money?
- Develops and patents novel therapeutic technologies.
- Conducts clinical trials to evaluate the safety and efficacy of its products.
- Seeks regulatory approval from agencies like the FDA.
- Commercializes approved products through direct sales or partnerships.
- Generates revenue through product sales, licensing agreements, and collaborations.
What Industry Does COEP Operate In?
Coeptis Therapeutics operates in the highly competitive biotechnology industry, characterized by rapid innovation, stringent regulatory requirements, and significant financial risks. The market for cancer therapies is substantial and growing, driven by an aging population and increasing cancer incidence rates. Companies like Coeptis face competition from established pharmaceutical giants and other emerging biotech firms. Success in this industry requires strong scientific expertise, effective clinical trial execution, and strategic partnerships to navigate the complex regulatory and commercial landscape. The industry is also subject to evolving market trends, including the rise of personalized medicine and the increasing importance of biomarkers in drug development.
Who Are COEP's Key Customers?
- Cancer patients suffering from CD38-related malignancies.
- Healthcare providers and oncologists prescribing cancer therapies.
- Hospitals and clinics administering cell therapy treatments.
- Pharmaceutical companies seeking to license or acquire novel therapies.
Coeptis Therapeutics, Inc. (COEP) Valuation Context
Valued at $38.62M, COEP is classified as a micro-cap stock. Relative to its peer group, COEP's quantitative score of 31/100 is below the peer average of 84/100.
COEP Revenue & Earnings Trend
In Q1 2026, COEP generated $114K in top-line revenue, marking a sequential decrease of 86.8%. The company recorded a net loss of $4.0M, with diluted EPS of $-0.65. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, COEP averaged $-0.62 in diluted EPS.
Company Profile
Coeptis Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Wexford, US. The company is led by CEO David Mehalick. COEP has traded publicly since 2020.
ROE -90%Key Financial Metrics
Return on equity for Coeptis Therapeutics, Inc. stands at -89.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -60.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -13.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.25 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -12.0%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 4/9Financial Health
Coeptis Therapeutics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.75 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Coeptis Therapeutics, Inc. revenue of about $1.0M for fiscal 2026, with EPS near $-3.40.
Net buyingInsider Activity
Over the past six months, Coeptis Therapeutics, Inc. insiders filed 18 SEC Form 4 transactions — 0 sales and 18 purchases. On net that is roughly 311K shares acquired (about $1.6M) — insiders putting money in tends to read as conviction.
COEP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Innovative cell therapy platforms.
- Focus on CD38-related cancers.
- Strategic collaborations with other companies.
- Development of companion diagnostics for personalized medicine.
Bear Case
- Limited financial resources.
- Early stage of development with no approved products.
- High dependence on clinical trial success.
- Small number of employees.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $113,771 | -$4M | -$0.65 |
| Q4 2025 | $862,049 | -$2M | -$0.29 |
| Q3 2025 | $237,441 | -$3M | -$0.58 |
| Q2 2025 | $200,681 | -$4M | -$0.95 |
Based on FMP financials and quantitative analysis
COEP Latest News
No recent news available for COEP.
COEP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for COEP.
Price Targets
Wall Street price target analysis for COEP.
COEP MoonshotScore
What does this score mean?
The MoonshotScore rates COEP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: David Mehalick
CEO
David Mehalick serves as the Chief Executive Officer of Coeptis Therapeutics, Inc. His background includes experience in managing and leading teams within the biopharmaceutical sector. He oversees the strategic direction of the company, focusing on the development and commercialization of innovative cancer therapies. His expertise lies in driving growth and fostering collaborations to advance the company's mission. He is responsible for the overall performance and success of Coeptis Therapeutics.
Track Record: Under David Mehalick's leadership, Coeptis Therapeutics has focused on advancing its pipeline of cell therapy platforms and pharmaceutical products for cancer patients. Key milestones include the development of CD38-GEAR-NK and CD38-Diagnostic, as well as strategic collaborations with Statera BioPharma and Vici Health Sciences. His tenure has been marked by efforts to secure funding and navigate the regulatory landscape to bring novel therapies to market.
What Investors Ask About Coeptis Therapeutics, Inc. (COEP) — Healthcare
What does Coeptis Therapeutics, Inc. do?
Coeptis Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing pharmaceutical products and cell therapy platforms for cancer patients. Their primary focus is on CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia. The company's lead product candidate is CD38-GEAR-NK, a Vy-Gen drug product designed to target these cancers. Additionally, Coeptis is developing CD38-Diagnostic, an in vitro screening tool to predict which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibody therapies. They also have collaborations to develop therapies for Crohn's and Parkinson's diseases.
What do analysts say about COEP stock?
Given Coeptis Therapeutics' small market capitalization and early stage of development, analyst coverage may be limited. Investors should conduct their own due diligence and consider the inherent risks associated with investing in early-stage biopharmaceutical companies. Key valuation metrics to consider include the potential market size for CD38-GEAR-NK and CD38-Diagnostic, as well as the company's ability to secure funding and achieve clinical trial milestones. Analyst consensus, if available, should be interpreted cautiously due to the speculative nature of the company's future prospects. No recommendations for buying or selling can be provided.
What are the main risks for COEP?
Coeptis Therapeutics faces several key risks inherent in the biopharmaceutical industry. These include the risk of clinical trial failures, regulatory delays, and competition from established pharmaceutical companies with greater resources. The company's financial position is also a significant risk, as it relies on securing additional funding to sustain operations. Furthermore, Coeptis faces the risk of patent infringement or challenges to its intellectual property rights. The company's small size and limited number of employees also pose operational risks.
What is Coeptis Therapeutics, Inc.'s drug pipeline status?
Coeptis Therapeutics, Inc.'s primary focus is on its CD38-GEAR-NK program, which is currently in the pre-clinical or early clinical stages targeting CD38-related cancers like multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia. The company is also developing CD38-Diagnostic, an in vitro screening tool designed to predict patient response to anti-CD38 therapies. Additionally, Coeptis has collaborations with Statera BioPharma to develop STAT-201 for Crohn's disease and with Vici Health Sciences, LLC to co-develop CPT60621 for Parkinson's Disease. The timelines for these programs depend on successful clinical trial outcomes and regulatory approvals.
How does Coeptis Therapeutics, Inc. manage patent expiration risks?
As an early-stage biopharmaceutical company, Coeptis Therapeutics, Inc.'s immediate focus is on securing and defending its intellectual property rights for its lead drug candidates and diagnostic tools. The company will need to actively manage the lifecycle of its patents to extend exclusivity and mitigate the impact of potential biosimilar competition. Strategies may include developing new formulations, obtaining additional patents on manufacturing processes, and pursuing regulatory exclusivity periods. The company's success in managing patent expiration risks will be critical to its long-term commercial viability.
What are the key factors to evaluate for COEP?
Coeptis Therapeutics, Inc. (COEP) holds an AI score of 31/100 (low). Not financial advice.
How frequently does COEP data refresh on this page?
COEP prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven COEP's recent stock price performance?
Coeptis Therapeutics, Inc. (COEP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative cell therapy platforms. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Financial data is limited and may not be fully comprehensive.
- Analyst opinions may vary and should be interpreted cautiously.